Museum of Science, Boston Announces 2024 Appointments to Its Board of Trustees

Priti is a successful entrepreneur, and as partner at NeoNet Capital she focuses on companies translating groundbreaking science into innovative products. Over the years, NeoNet has partnered with incredible entrepreneurs in fields ranging from healthcare analytics to energy storage. In 2019, she co-founded MarvelBiome Inc., a clinical stage company at the forefront of human microbiome research, developing microbial therapeutics for neurodegenerative diseases and other significant health challenges. Prior to NeoNet, as a founding member, she was involved in the growth of technology startups in the telecom and internet sectors. Notably, her first venture, Nexabit Networks, was acquired by Lucent Technologies in 1999. Priti holds six patents with more pending. Her leadership and advisory roles included serving as trustee of the Nashoba Brooks School (Concord, MA), member of the Johns Hopkins University President’s Parent Roundtable, and member of the Georgetown University Parent Leadership Council. Priti holds an MS from Boston College.

Doug is currently the managing partner of the KCap Biotechnology Fund, a long-oriented public equities fund, and serves on the boards of directors of several small biotechnology companies. Prior to launching KCap, Doug was founder, president & CEO of Dicerna Pharmaceuticals, an RNA interference-based genetic medicines company that was acquired by Novo Nordisk in 2021. Under more than a decade of Doug’s leadership, the company optimized and perfected its GalXC RNAi technology, creating the foundation for nearly 20 drug development programs and six major corporate collaborations, which to date has already resulted in an FDA-approved product. Prior to Dicerna, Doug was a general partner with the venture capital firm Oxford Bioscience Partners, where he specialized in financing innovative life science companies with transformative technologies, twice appearing on the Forbes Midas list. Prior to Oxford Bioscience Partners, Doug was a genomic scientist at the Whitehead/MIT Center for Genome Research, now known as the Broad Institute. Doug earned his AB from Cornell University and his PhD in genetics at the University of California, Berkeley. 

Sue Graham Johnston has spent her career at the intersection of innovation and operational excellence as an executive at numerous technology companies from start-ups to Fortune 500 companies including Juniper Networks, 128 Technology, Linde plc, Oracle, and Sun Microsystems. Sue holds a BS in Mechanical Engineering & Product Design, an MS in Manufacturing Systems Engineering and an MBA, all from Stanford University. She has a passion for engaging women and girls in STEM and participates in many professional and personal endeavors aimed at attracting, promoting, and retaining women in technology fields. She has been a Museum Advisor and Marathon runner for the Museum of Science and volunteers at the Exploratorium, a science museum in San Francisco. Sue serves on the Board of the San Francisco Opera where she is chair of the Audit Committee and vice-chair of the D&O committee. She currently lives in San Francisco with her husband Eric and their two cats, London and Boston.

Megan Greenfield is a partner at McKinsey and affiliated leader of the McKinsey Health Institute. She is a recognized leader in healthcare, health equity, and advancing equity in the workplace. Megan co-leads the McKinsey Boston office’s DEI efforts and has worked with regional and global organizations to design practical solutions for employers to drive diversity, equity, and inclusion. She is a frequent keynote speaker on McKinsey and LeanIn.org’s Women in the Workplace report, the largest- scale research on the status of women in corporate America. In 2023, she helped develop and launch the World Economic Forum’s Global Parity Alliance to increase equity in the workplace. In 2024 she released a global report on the impact of our underinvestment in women’s health at the World Economic Forum’s Annual Meeting in Davos “Closing the Women’s Health Gap: A Trillion Dollar Opportunity,” which has been mentioned in over 500 media outlets across the world reaching over 1 billion people. She is the vice chair of the Museum of Science Board of Advisors and is a World Economic Forum Young Global Leader. She received her BS from Caltech and PhD from Northwestern University, both in chemical engineering.

Katherine Relihan is manager of Lab Operations at Takeda Pharmaceuticals with a focus on supporting R&D Oncology Operations. With a BS in biochemistry, she brings over a decade of scientific learning and hands-on experience as a bench chemist to her current leadership role, where she has managed research and manufacturing labs for the past 10 years. Beyond her professional accomplishments, Katherine is deeply committed to strengthening the Boston community through non-profit engagement. A lifelong Museum of Science visitor and Boston resident, she has been an active volunteer and fundraiser for the Museum since joining the Boston Marathon team in 2014. Her passion for education extends beyond the Museum, with a focus on creating opportunities for Boston-area students, from youth programs to college scholarships. Katherine resides in Boston with her husband and dog.

Ricky joined Bain Capital Life Sciences in 2016 and is a partner. He is currently a member of the Board of Directors of Emalex, Adarx, and Tenacia. Previously he was a board member of Savara, Arcutis, Annexon, Avistone, and served as board observers of Pharvaris and Replimune. He also serves on the Harvard University Graduate School of Arts and Science Alumni Association Counsel. Prior to joining Bain Capital, from 2013 to 2016, he was a director of corporate development and strategy at Biogen. Prior to Biogen, Ricky served as a vice president at BlackRock, as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Ricky began his career as a senior scientist at Ironwood Pharmaceutical. Ricky received a PhD in chemistry and chemical biology from Harvard University and was an NIH post-doctoral fellow in biological chemistry & molecular pharmacology at Harvard Medical School. He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a BA in chemistry.